United States Pharmaceuticals

Akcea Therapeutics Inc (AKCA)

Track

Track

Ticker: AKCA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
McDevitt Damien Chief Executive Officer Executive Director
Transaction date
Sale
Price
53.35
Quantity 58,442 -41.6%
Value US$4,227,152
3.1
Jenne Kyle Chief Commercial Officer Officer
Transaction date
Sale
Price
19.08
Quantity 1,732 -40.4%
Value US$4,920,697
Patterson Joshua F. General Counsel Officer
Transaction date
Sale
Price
18.12
Quantity 319 -1.2%
Value US$5,780
Patterson Joshua F. General Counsel Officer
Transaction date
Sale
Price
12.50
Quantity 263 -1.0%
Value US$3,288
Patterson Joshua F. General Counsel Officer
Transaction date
Sale
Price
11.76
Quantity 335 -2.2%
Value US$3,938
O'Dea Louis Chief Medical Officer Officer
Transaction date
Sale
Price
11.75
Quantity 3,198 -4.9%
Value US$37,579
McDevitt Damien Chief Executive Officer Executive Director
Transaction date
Sale
Price
11.75
Quantity 9,417 -3.7%
Value US$110,649
3.1
Jenne Kyle Chief Commercial Officer Officer
Transaction date
Sale
Price
11.75
Quantity 779 -1.5%
Value US$9,153
3.5
Boyce Sarah President Executive Director
Transaction date
Sale
Price
23.52
Quantity 1,819 -8.4%
Value US$42,783
2.8
Soteropoulos Paula Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
32.17
Quantity 1,787 -100.0%
Value US$57,480
Goldberg Jeff Marc Chief Operating Officer
Transaction date
Planned sale
Price
31.72
Quantity 20,000 -87.4%
Value US$634,418
2.8
Soteropoulos Paula Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
32.11
Quantity 30,000 -100.0%
Value US$963,300
Goldberg Jeff Marc Chief Operating Officer
Transaction date
Planned sale
Price
31.71
Quantity 30,000 -91.2%
Value US$951,300
2.8
Soteropoulos Paula Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
32.14
Quantity 18,386 -100.0%
Value US$590,856
IONIS PHARMACEUTICALS INC Large shareholder
Transaction date
Purchase
Price
18.75
Quantity 10,666,666 +20.0%
Value US$199,999,988
IONIS PHARMACEUTICALS INC Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 3,125,000 +7.4%
Value US$25,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-10-14 2020-10-10 B Purchase
IONIS PHARMACEUTICALS INC
Large shareholder
86,460 +12.3%
321.38
US$2,909,350 		86,460 +12.3% 321.38 US$2,909,350
2020-09-24 2020-09-22 S Sale
McDevitt Damien

Chief Executive Officer

Executive Director
58,442 -41.6%
53.35
US$4,227,152 		58,442 -41.6% 53.35 US$4,227,152
2020-09-24 2020-09-22 S Sale
3.1
Jenne Kyle

Chief Commercial Officer

Officer
1,732 -40.4%
19.08
US$4,920,697 		1,732 -40.4% 19.08 US$4,920,697
2020-09-24 2020-09-22 S Sale
Patterson Joshua F.

General Counsel

Officer
319 -1.2%
18.12
US$5,780 		319 -1.2% 18.12 US$5,780
2020-07-20 2020-07-17 S Sale
Patterson Joshua F.

General Counsel

Officer
263 -1.0%
12.50
US$3,288 		263 -1.0% 12.50 US$3,288
2020-03-25 2020-03-23 S Sale
Patterson Joshua F.

General Counsel

Officer
335 -2.2%
11.76
US$3,938 		335 -2.2% 11.76 US$3,938
2020-03-25 2020-03-23 S Sale
O'Dea Louis

Chief Medical Officer

Officer
3,198 -4.9%
11.75
US$37,579 		3,198 -4.9% 11.75 US$37,579
2020-03-25 2020-03-23 S Sale
McDevitt Damien

Chief Executive Officer

Executive Director
9,417 -3.7%
11.75
US$110,649 		9,417 -3.7% 11.75 US$110,649
2020-03-25 2020-03-23 S Sale
3.1
Jenne Kyle

Chief Commercial Officer

Officer
779 -1.5%
11.75
US$9,153 		779 -1.5% 11.75 US$9,153
2019-07-17 2019-07-15 S Sale
3.5
Boyce Sarah

President

Executive Director
1,819 -8.4%
23.52
US$42,783 		1,819 -8.4% 23.52 US$42,783
2019-04-09 2019-04-08 PlS Planned sale
2.8
Soteropoulos Paula

Chief Executive Officer

Executive Director
1,787 -100.0%
32.17
US$57,480 		1,787 -100.0% 32.17 US$57,480
2019-04-09 2019-04-08 PlS Planned sale
Goldberg Jeff Marc

Chief Operating Officer
20,000 -87.4%
31.72
US$634,418 		20,000 -87.4% 31.72 US$634,418
2019-04-09 2019-04-05 PlS Planned sale
2.8
Soteropoulos Paula

Chief Executive Officer

Executive Director
30,000 -100.0%
32.11
US$963,300 		30,000 -100.0% 32.11 US$963,300
2019-04-09 2019-04-05 PlS Planned sale
Goldberg Jeff Marc

Chief Operating Officer
30,000 -91.2%
31.71
US$951,300 		30,000 -91.2% 31.71 US$951,300
2019-03-07 2019-03-06 PlS Planned sale
2.8
Soteropoulos Paula

Chief Executive Officer

Executive Director
18,386 -100.0%
32.14
US$590,856 		18,386 -100.0% 32.14 US$590,856
2018-04-19 2018-04-17 B Purchase IONIS PHARMACEUTICALS INC Large shareholder
10,666,666 +20.0%
18.75
US$199,999,988 		10,666,666 +20.0% 18.75 US$199,999,988
2017-07-21 2017-07-19 B Purchase IONIS PHARMACEUTICALS INC Large shareholder
3,125,000 +7.4%
8.00
US$25,000,000 		3,125,000 +7.4% 8.00 US$25,000,000
Explore more

More insider trading research around Akcea Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America